- Renowned virologist,
The event will feature presentation, discussion and Q&A with the following speakers:
John McHutchison , AO, MD, Chief Executive Officer at Assembly Bio- Applying unparalleled expertise in virologic drug development to expand Assembly Bio’s portfolio into new viral diseases
William Delaney , PhD, Chief Scientific Officer at Assembly Bio- Assembly Bio’s differentiated antiviral approach for HSV-2 and an early look at the program for transplant-associated herpesvirus infections
- Sir
Michael Houghton , PhD, Assembly Bio board member; Director of theLi Ka Shing Applied Virology Institute ,Li Ka Shing Professor in theDepartment of Medical Microbiology and Immunology , and Canada Excellence Chair in Virology at theUniversity of Alberta inEdmonton, Alberta ; jointly awarded 2020 Nobel Prize in Physiology or Medicine for the discovery of the hepatitis C virus
The live webcast will be available on the Events & Presentations page in the Investors section of Assembly Bio’s website and a replay will be accessible following the event. An accompanying slide presentation will also be available. To register for the live webcast and replay, please visit: https://investor.assemblybio.com/events-presentations.
About Assembly Biosciences
Assembly Bio is a clinical-stage biotechnology company pioneering the development of novel therapeutics for serious viral diseases. Assembly Bio is advancing a leading portfolio of more potent, next-generation core inhibitor drug candidates that aim to break the complex viral replication cycle of hepatitis B virus (HBV) to achieve finite and potentially curative therapies for the 296 million people living with HBV worldwide. The company’s research pipeline includes differentiated antiviral approaches against HBV/hepatitis delta virus and herpesviruses. For more information, visit assemblybio.com.
Forward-Looking Statements
The information in this press release contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to materially differ. These risks and uncertainties include: Assembly Bio’s ability to successfully execute its previously announced reprioritization and restructuring activities; potential adverse legal, reputational, operational and financial effects on Assembly Bio resulting from the reprioritization and restructuring activities; Assembly Bio’s ability to initiate and complete clinical studies involving its therapeutic product candidates, including studies contemplated by Assembly Bio’s collaboration agreements, in the currently anticipated timeframes; safety and efficacy data from clinical studies may not warrant further development of Assembly Bio’s product candidates; clinical and nonclinical data presented at conferences may not differentiate Assembly Bio’s product candidates from other companies’ candidates; results of nonclinical studies may not be representative of disease behavior in a clinical setting and may not be predictive of the outcomes of clinical studies; continued development and commercialization of ABI-H3733, if successful, in the
Contacts
Investor and Corporate:
SVP, Investor Relations, Corporate Affairs and Alliance Management
(415) 738-2992
sryan@assemblybio.com
Media:
Sam Brown Inc.
Hannah Hurdle
(805) 338-4752
ASMBMedia@sambrown.com
Source:
2022 GlobeNewswire, Inc., source